Bringing hope through science
Webcast - Oncopeptides withdraw Pepaxto in US, scale down organization and focus on R&D
October 22, Oncopeptides announced that the company has decided to withdraw Pepaxto® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA.
Investors, financial analysts, and media were invited to participate in a webcast including a Q&A the same day.
The event was hosted by CEO Marty J Duvall, CMO Klaas Bakker and CSO Jakob Lindberg. The presentation was held in English and was recorded.
Released
Interim report Q2 2021
Launch dynamics encouraging, but US regulatory situation challenging
CEO Marty J Duvall
See the Webcast See interview in Di.TV
For further information, please contact:
Linda Holmström
Director of Investor Relations
Q3 report November 4, 2021
linda.holmstrom@oncopeptides.com
+46 70 873 40 95
Press release -
Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D
Read press release
Upcoming events
-
-
-
08:00 CET
-
63rd ASH Annual Meeting & Exposition
-
-
-
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
Read more
Released
Annual Report 2020
“The past year was a transformational year for Oncopeptides highlighted by the FDA´s priority review of our NDA submission, which paved the way for an accelerated approval in the U.S. in early 2021.”
Marty J Duvall, CEO
Click here to watch the film where CEO Marty J Duvall summarizes a transformational year.
Annual Report 2020 - online version
For further information, please contact:
Linda Holmström
Director of Investor Relations
linda.holmstrom@oncopeptides.com
+46 70 873 40 95
Vision of Oncopeptides
“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
Cultures & Values
We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.